Doxorubicin promotes breast cancer cell migration and invasion via DCAF13

DDB1 and CUL4 associated factor 13 (DCAF13) is a substrate receptor in the CUL4‐DDB1 E3 ligase, and its expression is associated with the prognosis of certain cancers. In the present study, we report evidence that DCAF13 is aberrantly overexpressed in human breast cancer and its expression is positi...

Full description

Bibliographic Details
Main Authors: Zhaoran Sun, Dongmei Zhou, Jinkui Yang, Daoyong Zhang
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:FEBS Open Bio
Subjects:
Online Access:https://doi.org/10.1002/2211-5463.13330
_version_ 1798034297775456256
author Zhaoran Sun
Dongmei Zhou
Jinkui Yang
Daoyong Zhang
author_facet Zhaoran Sun
Dongmei Zhou
Jinkui Yang
Daoyong Zhang
author_sort Zhaoran Sun
collection DOAJ
description DDB1 and CUL4 associated factor 13 (DCAF13) is a substrate receptor in the CUL4‐DDB1 E3 ligase, and its expression is associated with the prognosis of certain cancers. In the present study, we report evidence that DCAF13 is aberrantly overexpressed in human breast cancer and its expression is positively associated with cancer progression. Further analysis showed that the DCAF13 expression level is significantly higher in triple‐negative breast cancer compared to non‐triple‐negative breast cancer, indicating a positive correlation between its expression and the aggressiveness of breast cancer. Subsequent studies revealed that DCAF13 regulates cancer cell migration, invasion and epithelial–mesenchymal transition in human breast cancer, whereas it has no significant impact on breast cancer cell proliferation, cell cycle progressionor apoptosis. Taken together, our results demonstrate that DCAF13 promotes the epithelial–mesenchymal transition in human breast cancer cells, indicating an involvement in breast cancer metastasis. Furthermore, we report that doxorubicin, a widely used chemotherapy drug, increases DCAF13 expression in breast cancer cells, leading to enhanced cancer cell migration and invasion. These results suggest that doxorubicin chemotherapy may increase the risk of metastasis of drug‐resistant breast cancer cells, and future therapeutics targeting DCAF13 may help reduce the risk, especially for patients undergoing chemotherapy.
first_indexed 2024-04-11T20:41:24Z
format Article
id doaj.art-1cffcf4db27245c3bcf72ea122d7c876
institution Directory Open Access Journal
issn 2211-5463
language English
last_indexed 2024-04-11T20:41:24Z
publishDate 2022-01-01
publisher Wiley
record_format Article
series FEBS Open Bio
spelling doaj.art-1cffcf4db27245c3bcf72ea122d7c8762022-12-22T04:04:11ZengWileyFEBS Open Bio2211-54632022-01-0112122123010.1002/2211-5463.13330Doxorubicin promotes breast cancer cell migration and invasion via DCAF13Zhaoran Sun0Dongmei Zhou1Jinkui Yang2Daoyong Zhang3Jiangsu Key Laboratory of Brain Disease and Bioinformation Research Center for Biochemistry and Molecular Biology Xuzhou Medical University ChinaGraduate School of Capital Medical University Beijing ChinaDepartment of Endocrinology Beijing Tongren Hospital Capital Medical University Beijing ChinaJiangsu Key Laboratory of Brain Disease and Bioinformation Research Center for Biochemistry and Molecular Biology Xuzhou Medical University ChinaDDB1 and CUL4 associated factor 13 (DCAF13) is a substrate receptor in the CUL4‐DDB1 E3 ligase, and its expression is associated with the prognosis of certain cancers. In the present study, we report evidence that DCAF13 is aberrantly overexpressed in human breast cancer and its expression is positively associated with cancer progression. Further analysis showed that the DCAF13 expression level is significantly higher in triple‐negative breast cancer compared to non‐triple‐negative breast cancer, indicating a positive correlation between its expression and the aggressiveness of breast cancer. Subsequent studies revealed that DCAF13 regulates cancer cell migration, invasion and epithelial–mesenchymal transition in human breast cancer, whereas it has no significant impact on breast cancer cell proliferation, cell cycle progressionor apoptosis. Taken together, our results demonstrate that DCAF13 promotes the epithelial–mesenchymal transition in human breast cancer cells, indicating an involvement in breast cancer metastasis. Furthermore, we report that doxorubicin, a widely used chemotherapy drug, increases DCAF13 expression in breast cancer cells, leading to enhanced cancer cell migration and invasion. These results suggest that doxorubicin chemotherapy may increase the risk of metastasis of drug‐resistant breast cancer cells, and future therapeutics targeting DCAF13 may help reduce the risk, especially for patients undergoing chemotherapy.https://doi.org/10.1002/2211-5463.13330breast cancerchemotherapyDCAF13doxorubicinEMTmetastasis
spellingShingle Zhaoran Sun
Dongmei Zhou
Jinkui Yang
Daoyong Zhang
Doxorubicin promotes breast cancer cell migration and invasion via DCAF13
FEBS Open Bio
breast cancer
chemotherapy
DCAF13
doxorubicin
EMT
metastasis
title Doxorubicin promotes breast cancer cell migration and invasion via DCAF13
title_full Doxorubicin promotes breast cancer cell migration and invasion via DCAF13
title_fullStr Doxorubicin promotes breast cancer cell migration and invasion via DCAF13
title_full_unstemmed Doxorubicin promotes breast cancer cell migration and invasion via DCAF13
title_short Doxorubicin promotes breast cancer cell migration and invasion via DCAF13
title_sort doxorubicin promotes breast cancer cell migration and invasion via dcaf13
topic breast cancer
chemotherapy
DCAF13
doxorubicin
EMT
metastasis
url https://doi.org/10.1002/2211-5463.13330
work_keys_str_mv AT zhaoransun doxorubicinpromotesbreastcancercellmigrationandinvasionviadcaf13
AT dongmeizhou doxorubicinpromotesbreastcancercellmigrationandinvasionviadcaf13
AT jinkuiyang doxorubicinpromotesbreastcancercellmigrationandinvasionviadcaf13
AT daoyongzhang doxorubicinpromotesbreastcancercellmigrationandinvasionviadcaf13